Advertisement

HindustanTimes Sun,20 Apr 2014

Sun Pharma Q3 net up 32%

HT Correspondent, Hindustan Times  Mumbai, February 08, 2013
First Published: 21:18 IST(8/2/2013) | Last Updated: 21:20 IST(8/2/2013)

Sun Pharmaceutical Inds on Friday announced a 32% year-on-year growth in consolidated net profit to Rs. 881.30 crore for the quarter ended December from Rs. 668.30 crore in the same period a year ago, driven by strong sales in the United States market.

Advertisement

Sales of branded prescription formulations in US rose 44% to Rs. 1,495 crore from Rs. 1,040 crore in the same quarter previous year. The US sales accounted for 52% of total sales during the quarter.

"All our businesses continue to perform in-line with our expectations. The acquisition of DUSA and URL's generic business will further strengthen our presence in the US," said Dilip Shanghvi, MD, Sun Pharmaceutical.

US-based Dusa, a dermatology company, was acquired by Sun pharma for around R1,250 crore last year. Caraco Pharma, Sun Pharma's wholly-owned subsidiary, also announced the acquisition of URL Pharma Inc's generic business in US, during the quarter.

Advertisement
more from Business

700 trainees opt for exit plan at Nokia’s Chennai plant

Finnish handset maker Nokia, struggling to shepherd its Chennai plant into its agreement to be bought by US software giant Microsoft amid tax disputes in India, has got some success with 736 of its trainees accepting the voluntary separation scheme.
markets
Advertisement
Most Popular
Advertisement
Copyright © 2014 HT Media Limited. All Rights Reserved